Key facts
- Notable investors include HSG (Hong Kong), Addor Capital, Jolmo Investment, Suzhou Guofa Venture Capital, Suzhou Wuzhong Jinkong Equity Investment Management — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Hiwemed
- ·The full record, as it builds
Funding rounds
No funding rounds for Hiwemed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hiwemed
Developer of vascular interventional embolization products intended to meet clinical needs. The company provides drug delivery products and a combination of medicine and equipment solutions for clinical use, and serves patients with cancer, uterine fibroids, prostate, osteoarthritis, etc, is positioned to develop new biomaterials and the products can be used for vascular intervention, tissue intervention, cavity intervention and other treatment methods, enabling efficient chronic tumor management for the users.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Employees
- 40
- Website
- hiwemed.com/
- Ownership
- Privately Held (backing)
Hiwemed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hiwemed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hiwemed in its N-PORT filings yet. We sweep new filings monthly.